WuXi AppTec highlights compliance controls in global partnerships

WuXi AppTec said it is building customer and supplier relationships around strict compliance, transparency and oversight across its global drug development and manufacturing work. The company pointed to 2025 audit results, international certifications and its 2025 entry into the Pharmaceutical Supply Chain Initiative as evidence of its approach. Why it matters: - WuXi AppTec is signaling to customers, regulators and industry partners that compliance is a core part of its business model in a heavily regulated sector. - The company says its controls are designed to reduce risk in customer onboarding, supplier management and project execution across the pharmaceutical and life sciences supply chain. - Strong compliance and data security practices can affect whether drug developers choose a contract research, development and manufacturing partner. What happened: - WuXi AppTec outlined its compliance, transparency and responsible business conduct practices in a June 10, 2026 statement. - The company said it uses multi-tiered due diligence for all partnerships, including Know-Your-Customer and Know-Your-Supplier procedures. - WuXi AppTec said it joined the Pharmaceutical Supply Chain Initiative in 2025 as a Supplier Partner. - The company said its customers span more than 30 countries and include commercial pharmaceutical and biotechnology organizations. The details: - WuXi AppTec said supplier management includes selection, ongoing evaluation, regular performance reviews and periodic audits to check supply quality and stability. - The company said drug development and manufacturing are regulated by authorities including the U.S. Food and Drug Administration, the European Medicines Agency and China’s National Medical Products Administration. - WuXi AppTec said its facilities hold multiple accreditations and comply with Good Laboratory Practice, Good Manufacturing Practice and other standards. - The company said it has worked for more than 25 years with global customers and has passed audits and inspections across jurisdictions, including U.S. government scrutiny. - WuXi AppTec said it works with companies ranging from biotech startups to multinational pharmaceutical firms in more than 30 countries. - In 2025, the company said it completed 741 quality audits and inspections, including 680 customer audits, 56 regulatory inspections and five independent third-party audits. - WuXi AppTec said those 2025 reviews produced zero critical findings. - The company said its 20 main sites were ISO/IEC certified in 2025. - WuXi AppTec said it operates under a data privacy and intellectual property protection framework aligned with applicable laws and standards. - The company said U.S.-based project information is stored only in U.S.-based facilities and IT systems, with access limited to authorized personnel. - WuXi AppTec said it had 60 information security audits by global customers in 2025 with zero critical findings. Between the lines: - The statement reads as both a compliance update and a reputation defense in an industry where regulatory trust can shape partnerships and market access. - The repeated emphasis on audits, certifications and zero critical findings suggests WuXi AppTec wants to foreground operational controls over broader political or commercial debate. - The company is also tying data security and supplier oversight to its value proposition as a global contract research, development and manufacturing organization. What’s next: - WuXi AppTec said it will continue maintaining its compliance and transparency standards as it works with the global pharmaceutical and life sciences community. - The company is positioning ongoing regulatory oversight, customer audits and internal controls as part of its long-term operating model. The bottom line: - WuXi AppTec is making compliance itself part of the pitch: a global drug-development partner that says it can meet strict regulatory, quality and security expectations at scale.